BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 38768405)

  • 1. State-of-the-Art Management of Colorectal Cancer: Treatment Advances and Innovation.
    Pathak PS; Chan G; Deming DA; Chee CE
    Am Soc Clin Oncol Educ Book; 2024 Jun; 44(3):e438466. PubMed ID: 38768405
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sidedness Matters: Surrogate Biomarkers Prognosticate Colorectal Cancer upon Anatomic Location.
    Ben-Aharon I; Goshen-Lago T; Sternschuss M; Morgenstern S; Geva R; Beny A; Dror Y; Steiner M; Hubert A; Idelevich E; Shulman K; Mishaeli M; Man S; Liebermann N; Soussan-Gutman L; Brenner B
    Oncologist; 2019 Aug; 24(8):e696-e701. PubMed ID: 30755502
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Precision medicine for metastatic colorectal cancer: an evolving era.
    Guler I; Askan G; Klostergaard J; Sahin IH
    Expert Rev Gastroenterol Hepatol; 2019 Oct; 13(10):919-931. PubMed ID: 31475851
    [No Abstract]   [Full Text] [Related]  

  • 4. Molecular Testing for the Treatment of Advanced Colorectal Cancer: An Overview.
    Lin PS; Semrad TJ
    Methods Mol Biol; 2018; 1765():281-297. PubMed ID: 29589315
    [TBL] [Abstract][Full Text] [Related]  

  • 5. From tumour heterogeneity to advances in precision treatment of colorectal cancer.
    Punt CJ; Koopman M; Vermeulen L
    Nat Rev Clin Oncol; 2017 Apr; 14(4):235-246. PubMed ID: 27922044
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of biomarkers and primary tumor location on the metastatic colorectal cancer first-line treatment landscape in five European countries.
    Kafatos G; Banks V; Burdon P; Neasham D; Lowe KA; Anger C; Manuguid F; Trojan J
    Future Oncol; 2021 Apr; 17(12):1495-1505. PubMed ID: 33464120
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Genetic and epigenetic biomarkers for diagnosis, prognosis and treatment of colorectal cancer.
    Coppedè F; Lopomo A; Spisni R; Migliore L
    World J Gastroenterol; 2014 Jan; 20(4):943-56. PubMed ID: 24574767
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of sidedness of colorectal cancer on tumor immunity.
    Takasu C; Nishi M; Yoshikawa K; Tokunaga T; Kashihara H; Yoshimoto T; Shimada M
    PLoS One; 2020; 15(10):e0240408. PubMed ID: 33045001
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeted therapy for colorectal cancer metastases: A review of current methods of molecularly targeted therapy and the use of tumor biomarkers in the treatment of metastatic colorectal cancer.
    Piawah S; Venook AP
    Cancer; 2019 Dec; 125(23):4139-4147. PubMed ID: 31433498
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Systemic Therapy for Metastatic Colorectal Cancer: From Current Standards to Future Molecular Targeted Approaches.
    Atreya CE; Yaeger R; Chu E
    Am Soc Clin Oncol Educ Book; 2017; 37():246-256. PubMed ID: 28561718
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Current and evolving biomarkers for precision oncology in the management of metastatic colorectal cancer.
    Henry JT; Johnson B
    Chin Clin Oncol; 2019 Oct; 8(5):49. PubMed ID: 31500426
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Consensus molecular subtypes (CMS) in metastatic colorectal cancer - personalized medicine decision.
    Rebersek M
    Radiol Oncol; 2020 May; 54(3):272-277. PubMed ID: 32463385
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Biomarker-guided therapy for colorectal cancer: strength in complexity.
    Sveen A; Kopetz S; Lothe RA
    Nat Rev Clin Oncol; 2020 Jan; 17(1):11-32. PubMed ID: 31289352
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Molecular Profiling in Metastatic Colorectal Cancer.
    Armstrong SA; Malley R; Weinberg BA
    Oncology (Williston Park); 2020 Sep; 34(9):352-355. PubMed ID: 32965665
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Chasing the personalized medicine dream through biomarker validation in colorectal cancer.
    Patil H; Saxena SG; Barrow CJ; Kanwar JR; Kapat A; Kanwar RK
    Drug Discov Today; 2017 Jan; 22(1):111-119. PubMed ID: 27693431
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluating the recent developments in palliative chemotherapy for metastatic colorectal cancer.
    Baek SK; Lee KT; Bae SB; Lee SC
    Korean J Intern Med; 2019 Nov; 34(6):1188-1196. PubMed ID: 31346151
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Personalized treatment for colorectal cancer: novel developments and putative therapeutic strategies.
    Akkad J; Bochum S; Martens UM
    Langenbecks Arch Surg; 2015 Feb; 400(2):129-43. PubMed ID: 25701352
    [TBL] [Abstract][Full Text] [Related]  

  • 18. MicroRNAs as novel predictive biomarkers and therapeutic targets in colorectal cancer.
    Stiegelbauer V; Perakis S; Deutsch A; Ling H; Gerger A; Pichler M
    World J Gastroenterol; 2014 Sep; 20(33):11727-35. PubMed ID: 25206276
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Colorectal cancer: from prevention to personalized medicine.
    Binefa G; Rodríguez-Moranta F; Teule A; Medina-Hayas M
    World J Gastroenterol; 2014 Jun; 20(22):6786-808. PubMed ID: 24944469
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical Challenges of Consensus Molecular Subtype CMS4 Colon Cancer in the Era of Precision Medicine.
    Mouillet-Richard S; Cazelles A; Sroussi M; Gallois C; Taieb J; Laurent-Puig P
    Clin Cancer Res; 2024 Jun; 30(11):2351-2358. PubMed ID: 38564259
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.